198 related articles for article (PubMed ID: 38010388)
41. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity.
Schwartz Z; Bowe RB; Coleman M; Magro CM
Ann Diagn Pathol; 2018 Dec; 37():57-61. PubMed ID: 30292067
[TBL] [Abstract][Full Text] [Related]
42. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders.
Vonderheid EC; Sajjadian A; Kadin ME
J Am Acad Dermatol; 1996 Mar; 34(3):470-81. PubMed ID: 8609262
[TBL] [Abstract][Full Text] [Related]
43. Lymphomatoid papulosis type A: clinical, morphologic, and immunophenotypic study.
Sioutos N; Asvesti C; Sivridis E; Aygerinou G; Tsega A; Zakopoulou N; Zographakis I
Int J Dermatol; 1997 Jul; 36(7):514-7. PubMed ID: 9268749
[TBL] [Abstract][Full Text] [Related]
44. Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
Greisser J; Palmedo G; Sander C; Kutzner H; Kazakov DV; Roos M; Burg G; Kempf W
J Cutan Pathol; 2006 Nov; 33(11):711-5. PubMed ID: 17083688
[TBL] [Abstract][Full Text] [Related]
45. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
[TBL] [Abstract][Full Text] [Related]
47. [Detection of chromosomal translocations of DUSP22 and TP63 in ALK-negative anaplastic large cell lymphoma by fluorescence in situ hybridization and related clinical relevance].
Wang C; Chen X; Chen XY; He YH
Zhonghua Bing Li Xue Za Zhi; 2019 Oct; 48(10):791-795. PubMed ID: 31594044
[No Abstract] [Full Text] [Related]
48. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with
Luchtel RA; Dasari S; Oishi N; Pedersen MB; Hu G; Rech KL; Ketterling RP; Sidhu J; Wang X; Katoh R; Dogan A; Kip NS; Cunningham JM; Sun Z; Baheti S; Porcher JC; Said JW; Jiang L; Hamilton-Dutoit SJ; Møller MB; Nørgaard P; Bennani NN; Chng WJ; Huang G; Link BK; Facchetti F; Cerhan JR; d'Amore F; Ansell SM; Feldman AL
Blood; 2018 Sep; 132(13):1386-1398. PubMed ID: 30093402
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L.
Sigel JE; Hsi ED
Mod Pathol; 2000 Apr; 13(4):446-51. PubMed ID: 10786813
[TBL] [Abstract][Full Text] [Related]
50.
Wang M; Kibbi N; Ring N; Siddon A; Foss F; Totonchy M
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31570354
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
52. Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea.
Kim YC; Yang WI; Lee MG; Kim SN; Cho KH; Lee SJ; Lee MW; Koh JK
Int J Dermatol; 2006 Nov; 45(11):1312-6. PubMed ID: 17076712
[TBL] [Abstract][Full Text] [Related]
53. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis.
McQuitty E; Curry JL; Tetzlaff MT; Prieto VG; Duvic M; Torres-Cabala C
J Cutan Pathol; 2014 Feb; 41(2):88-100. PubMed ID: 24118002
[TBL] [Abstract][Full Text] [Related]
54. Clonal T-cell receptor β-chain gene rearrangements in differential diagnosis of lymphomatoid papulosis from skin metastasis of nodal anaplastic large-cell lymphoma.
Akilov OE; Pillai RK; Grandinetti LM; Kant JA; Geskin L
Arch Dermatol; 2011 Aug; 147(8):943-7. PubMed ID: 21844453
[TBL] [Abstract][Full Text] [Related]
55. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
[TBL] [Abstract][Full Text] [Related]
56. A comparison of clinical, morphological and immunohistochemical features of lymphomatoid papulosis and primary cutaneous CD30(Ki-1)-positive anaplastic large cell lymphoma.
Tomaszewski MM; Lupton GP; Krishnan J; May DL
J Cutan Pathol; 1995 Aug; 22(4):310-8. PubMed ID: 7499570
[TBL] [Abstract][Full Text] [Related]
57. Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.
Xerri L; Adélaïde J; Avenin M; Guille A; Taix S; Bonnet N; Carbuccia N; Garnier S; Mescam L; Murati A; Chaffanet M; Coso D; Bouabdallah R; Bertucci F; Birnbaum D
Histopathology; 2019 Mar; 74(4):654-662. PubMed ID: 30393995
[TBL] [Abstract][Full Text] [Related]
58. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases.
Plaza JA; Feldman AL; Magro C
J Cutan Pathol; 2013 Feb; 40(2):236-47. PubMed ID: 23189966
[TBL] [Abstract][Full Text] [Related]
59. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma.
Yagi H; Tokura Y; Furukawa F; Takigawa M
J Invest Dermatol; 1996 Dec; 107(6):827-32. PubMed ID: 8941669
[TBL] [Abstract][Full Text] [Related]
60. CD30-positive lymphoproliferative disorders arising after regional therapy for recurrent melanoma: a report of two cases and analysis of CD30 expression.
Gill K; Ariyan C; Wang X; Brady MS; Pulitzer M
J Surg Oncol; 2014 Sep; 110(3):258-64. PubMed ID: 24891295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]